thalidomide has been researched along with Osteonecrosis in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Osteonecrosis: Death of a bone or part of a bone, either atraumatic or posttraumatic.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Osteonecrosis of the jaw (ONJ) is an emerging serious side effect of the new generation bisphosphonates with a growing number of reports related to this pathological entity." | 7.75 | Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. ( Aki, SZ; Cetiner, M; Cetiner, S; Gultekin, SE; Haznedar, R; Kahraman, SA; Kocakahyaoglu, B; Sucak, GT, 2009) |
| " Osteonecrosis of the jaw (ONJ) is an emerging serious side effect of the new generation bisphosphonates with a growing number of reports related to this pathological entity." | 3.75 | Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. ( Aki, SZ; Cetiner, M; Cetiner, S; Gultekin, SE; Haznedar, R; Kahraman, SA; Kocakahyaoglu, B; Sucak, GT, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dimopoulos, MA | 1 |
| Kastritis, E | 1 |
| Bamia, C | 1 |
| Melakopoulos, I | 1 |
| Gika, D | 1 |
| Roussou, M | 1 |
| Migkou, M | 1 |
| Eleftherakis-Papaiakovou, E | 1 |
| Christoulas, D | 1 |
| Terpos, E | 1 |
| Bamias, A | 1 |
| Cetiner, S | 1 |
| Sucak, GT | 1 |
| Kahraman, SA | 1 |
| Aki, SZ | 1 |
| Kocakahyaoglu, B | 1 |
| Gultekin, SE | 1 |
| Cetiner, M | 1 |
| Haznedar, R | 1 |
| Tosi, P | 1 |
| Zamagni, E | 1 |
| Cangini, D | 1 |
| Tacchetti, P | 1 |
| Di Raimondo, F | 1 |
| Catalano, L | 1 |
| D'Arco, A | 1 |
| Ronconi, S | 1 |
| Cellini, C | 1 |
| Offidani, M | 1 |
| Perrone, G | 1 |
| Ceccolini, M | 1 |
| Brioli, A | 1 |
| Tura, S | 1 |
| Baccarani, M | 1 |
| Cavo, M | 1 |
| Stoopler, ET | 1 |
| Vogl, DT | 1 |
| Stadtmauer, EA | 1 |
1 trial available for thalidomide and Osteonecrosis
| Article | Year |
|---|---|
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Dexamethasone; Dip | 2006 |
3 other studies available for thalidomide and Osteonecrosis
| Article | Year |
|---|---|
Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Boronic Aci | 2009 |
Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Resorption; Dexamethasone; Diphosphonates; Femal | 2009 |
Medical management update: multiple myeloma.
Topics: Adrenal Cortex Hormones; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Combined | 2007 |